R-roscovitine reduces lung inflammation induced by Lipoteichoic acid and Streptococcus pneumoniae

Molecular Medicine

Volumn 18, Issue 7, 2012, Pages 1086-1095

  Hoogendijk, Arie J ^a   Roelofs, Joris J T H ^a   Duitman, JanWillem ^a   van Lieshout, Miriam H P ^a   Blok, Dana C ^a   van der Poll, Tom ^a   Wieland, Catharina W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; CHEMOATTRACTANT; CYCLIN DEPENDENT KINASE; ROSCOVITINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL LOAD; BACTERIAL PNEUMONIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG LAVAGE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; APOPTOSIS; BRONCHOALVEOLAR LAVAGE FLUID; CASPASE 3; CELL LINE; CHEMOKINES; CYCLIN-DEPENDENT KINASES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; NEUTROPHILS; PNEUMONIA; PURINES; STREPTOCOCCUS PNEUMONIAE; TEICHOIC ACIDS;

EID: 84866764681     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00033     Document Type: Article

References (46)

1. Tsai KS, Grayson MH. (2008) Pulmonary defense mechanisms against pneumonia and sepsis. Curr. Opin. Pulm. Med. 14:260-5.
2. Anderson RN, Smith BL. (2005) Deaths: leading causes for 2002. Natl. Vital Stat. Rep. 53:1-89.
3. Niederman MS, et al. (2001) Guidelines for the Management of Adults with Communityacquired Pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163:1730-54.
4. Feikin DR, et al. (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am. J. Public Health 90:223-9.
5. Klugman KP. (1990) Pneumococcal resistance to antibiotics. Clin. Microbiol. Rev. 3:171-96.
6. File JTM. (2003) Community-acquired pneumonia. Lancet. 362:1991-2001.
7. Ginsburg I. (2002) Role of lipoteichoic acid in infection and inflammation. Lancet Infect. Dis. 2:171-9.
8. Leemans JC, Vervoordeldonk MJBM, Florquin S, van Kessel KP, van der Poll T. (2002) Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am. J. Respir. Crit. Care Med. 165:1445-50.
9. Knapp S, et al. (2008) Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the plateletactivating factor receptor. J. Immunol. 180:3478-84.
10. Leitch AE, Haslett C, Rossi AG. (2009) Cyclindependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br. J. Pharmacol. 158:1004-16.
11. Haslett C. (1999) Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am. J. Respir. Crit. Care Med. 160:S5-11.
12. Craig A, Mai J, Cai S, Jeyaseelan S. (2009) Neutrophil recruitment to the lungs during bacterial pneumonia. Infect. Immun. 77:568-75.
13. Bianchi SM, Dockrell DH, Renshaw SA, Sabroe I, Whyte MKB. (2006) Granulocyte apoptosis in the pathogenesis and resolution of lung disease. Clin. Sci. 110:293-304.
14. Droemann D, et al. (2000) Decreased apoptosis and increased activation of alveolar neutrophils in bacterial pneumonia. Chest. 117:1679-84.
15. Fadok VA, et al. (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J. Clin. Invest. 101:890-8.
16. Huynh M-LN, Fadok VA, Henson PM. (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-p1 secretion and the resolution of inflammation. J. Clin. Invest. 109:41-50.
17. Bach S, et al. (2005) Roscovitine targets, protein kinases and pyridoxal kinase. J. Biol. Chem. 280:31208-19.
18. Goodyear S, Sharma MC. (2007) Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5. Exp. Mol. Pathol. 82:25-32.
19. Jhou R-S, et al. (2009) Inhibition of cyclindependent kinases by olomoucine and roscovitine reduces lipopolysaccharide-induced inflammatory responses via down-regulation of nuclear factor kB. Cell Prolif. 42:141-9.
20. Rossi AG, et al. (2006) Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nat. Med. 12:1056-64.
21. Duffin R, et al. (2009) The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1. FEBS Lett. 583:2540-6.
22. Koedel U, et al. (2009) Apoptosis is essential for neutrophil functional shutdown and determines tissue damage in experimental pneumococcal meningitis. PLoS Pathog. 5:e1000461.
23. Rijneveld AW, Florquin S, Hartung T, Speelman P, Poll T. (2003) Anti-tumor necrosis factor antibody impairs the therapeutic effect of ceftriaxone in murine pneumococcal pneumonia. J. Infect. Dis. 188:282-5.
24. Schouten M, et al. (2010) Therapeutic recombinant murine activated protein C attenuates pulmonary coagulopathy and improves survival in murine pneumococcal pneumonia. J. Infect. Dis. 202:1600-7.
25. Wieland CW, Stegenga ME, Florquin S, Fantuzzi G, van der Poll T. (2006) Leptin and host defense against gram-positive and gram-negative pneumonia in mice. Shock. 25:414-9.
26. Knapp S, et al. (2004) Toll-like receptor 2 plays a role in the early inflammatory response to murine pneumococcal pneumonia but does not contribute to antibacterial defense. J. Immunol. 172:3132-8.
27. Knockaert M, Greengard P, Meijer L. (2002) Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:417-25.
28. Du J, et al. (2009) Inhibition of CDKs by roscovitine suppressed LPS-induced *NO production through inhibiting NF{kappa}B activation and BH4 biosynthesis in macrophages. Am. J. Physiol. Cell Physiol. 297:C742-9.
29. Vermes I, Haanen C, Steffens-Nakken H, Reutellingsperger C. (1995) A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Meth. 184:39-51.
30. Van Den Boogaard FE, et al. (2011) Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. J. Thromb. Haemost. 9:122-32.
31. van der Poll T, Opal SM. (2009) Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet. 374:1543-56.
32. Takeuchi O, Akira S. (2010) Pattern recognition receptors and inflammation. Cell. 140:805-20.
33. Jeyaseelan S, et al. (2006) Toll/IL-1R domaincontaining adaptor protein (TIRAP) is a critical mediator of antibacterial defense in the lung against Klebsiella pneumoniae but not Pseudo-monas aeruginosa. J. Immunol. 177:538-47.
34. Brown KA, et al. (2006) Neutrophils in development of multiple organ failure in sepsis. Lancet. 368:157-69.
35. Cross A, Moots RJ, Edwards SW. (2008) The dual effects of TNF{alpha} on neutrophil apoptosis are mediated via differential effects on expression of Mcl-1 and Bfl-1. Blood. 111:878-84.
36. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. (2007) R-Roscovitine simultaneously targets both the p53 and NF-[kappa]B pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ. 15:263-73.
37. Leitch AE, et al. (2010) The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-inflammatory signalling and drive neutrophil apoptosis. Eur. J. Immunol. 40:1127-38.
38. Lotz S, et al. (2004) Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. J. Leukocyte Biol. 75:467-77.
39. Farahi N, et al. (2011) Effects of the cyclindependent kinase inhibitor R-roscovitine on eosinophil survival and clearance. Clin. Exp. Allergy. 41:673-87.
40. Alcorta DA, et al. (1996) Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 93:13742-7.
41. Lum JJ, Bren G, McClure R, Badley AD. (2005) Elimination of senescent neutrophils by TNFrelated apoptosis-inducing ligand. J. Immunol. 175:1232-8.
42. Mantovani A, Cassatella MA, Costantini C, Jaillon S. (2011) Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol.11:519-31.
43. Bergeron Y, et al. (1998) Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice. Infect. Immun. 66:912-22.
44. Giebelen IA, Leendertse M, Florquin S, van der Poll T. (2009) Stimulation of acetylcholine receptors impairs host defence during pneumococcal pneumonia. Eur. Respir. J. 33:375-81.
45. Benson C, et al. (2007) A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer. 96:29-37.
46. Hsieh W-S, et al. (2009) Pharmacodynamic effects of Seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer. Clin. Cancer Res. 15:1435-42.